Fixing NIH peer review

Re: How to fix peer review.1 I currently serve on review panels for the Department of Defense Congressionally-Directed Medical Research Programs in breast and prostate cancers. A stated goal of this funding program is to stress innovation. That makes it unlike NIH programs that require extensive preliminary data – typically the first specific aim of the grant – and are looking for the next logical step in a non-controversial research plan. While the DOD research proposal is significa

Written byDavid Adams
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Re: How to fix peer review.1 I currently serve on review panels for the Department of Defense Congressionally-Directed Medical Research Programs in breast and prostate cancers. A stated goal of this funding program is to stress innovation. That makes it unlike NIH programs that require extensive preliminary data – typically the first specific aim of the grant – and are looking for the next logical step in a non-controversial research plan. While the DOD research proposal is significantly shorter than NIH (6 vs. 25 pages), a full application can easily run over one hundred pages. With funding rates for DOD Idea grants (analogous to NIH RO1's) dropping to 3% this past cycle, a large number of investigators – not to mention grants administrators and reviewers – waste much valuable time and effort on the application process. The parallels to NIH applicants, with a success rate of around 16%, are clear.

...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • The Scientist Placeholder Image

    I currently serve on review panels for the Department of Defense Congressionally-Directed Medical Research Programs in breast and prostate cancers.

    View Full Profile

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies